Fragment-based Approaches in Drug Discovery
Wolfgang Jahnke · Daniel A. Erlanson · Raimund Mannhold · Hugo Kubinyi · Gerd Folkers
2006-ж. дек. · John Wiley & Sons
Электрондук китеп
391
Барактар
reportРейтинг жана сын-пикирлер текшерилген жок Кеңири маалымат
Учкай маалымат
This first systematic summary of the impact of fragment-based approaches on the drug development process provides essential information that was previously unavailable. Adopting a practice-oriented approach, this represents a book by professionals for professionals, tailor-made for drug developers in the pharma and biotech sector who need to keep up-to-date on the latest technologies and strategies in pharmaceutical ligand design. The book is clearly divided into three sections on ligand design, spectroscopic techniques, and screening and drug discovery, backed by numerous case studies.
Автор жөнүндө
Wolfgang Jahnke is a Senior Research Investigator at the Novartis Institutes for Biomedical Research in Basel, Switzerland, where he leads the Fragment-Based Screening technology platform. During his ten years at Novartis, he has received several honors, among them the appointment as Scientific Expert, and the Leading Scientist Award. Dr. Jahnke received his PhD from the TU Munchen, working with Horst Kessler on the development and application of novel NMR methods. He subsequently carried out research with Peter Wright at the Scripps Research Institute in La Jolla.
Daniel A. Erlanson joined Sunesis Pharmaceuticals at its inception in 1998. He has been instrumental in inventing its drug-discovery technologies and using these to design leads against a variety of disease targets. Prior to Sunesis, Dr. Erlanson developed methods to conformationally constrain peptides as a post-doctoral fellow with James A. Wells at Genentech. Dr. Erlanson received his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College, MN.
Daniel A. Erlanson joined Sunesis Pharmaceuticals at its inception in 1998. He has been instrumental in inventing its drug-discovery technologies and using these to design leads against a variety of disease targets. Prior to Sunesis, Dr. Erlanson developed methods to conformationally constrain peptides as a post-doctoral fellow with James A. Wells at Genentech. Dr. Erlanson received his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College, MN.
Бул электрондук китепти баалаңыз
Оюңуз менен бөлүшүп коюңуз.
Окуу маалыматы
Смартфондор жана планшеттер
Android жана iPad/iPhone үчүн Google Play Китептер колдонмосун орнотуңуз. Ал автоматтык түрдө аккаунтуңуз менен шайкештелип, кайда болбоңуз, онлайнда же оффлайнда окуу мүмкүнчүлүгүн берет.
Ноутбуктар жана компьютерлер
Google Play'ден сатылып алынган аудиокитептерди компьютериңиздин веб браузеринен уга аласыз.
eReaders жана башка түзмөктөр
Kobo eReaders сыяктуу электрондук сыя түзмөктөрүнөн окуу үчүн, файлды жүктөп алып, аны түзмөгүңүзгө өткөрүшүңүз керек. Файлдарды колдоого алынган eReaders'ке өткөрүү үчүн Жардам борборунун нускамаларын аткарыңыз.
